31/01/2026
BREAKING THE 50-YEAR DEADLOCK 🧬🚨
​For nearly half a century, pancreatic cancer has been medicine’s most "unbeatable" foe. While other cancers saw survival rates climb, pancreatic cancer remained stuck in a 50-year stalemate, until now.
​In a landmark breakthrough (January 2026), Dr. Mariano Barbacid and his team at the Spanish National Cancer Research Centre (CNIO) have achieved something once thought impossible: The complete and permanent elimination of pancreatic cancer in experimental models.
​Why is this a massive deal?
Pancreatic cancer is notoriously "clever." When you block one growth pathway, the tumor simply "rewires" itself and finds a detour. This is why single-drug treatments almost always fail.
​The "Triple-Drug" Strategy:
Barbacid’s team stopped playing "whack-a-mole" and instead launched a coordinated three-pronged attack:
​Cut the Engine: Using Daraxonrasib to block the KRAS mutation (the "gas pedal" for 90% of these tumors).
​Seal the Exits: Using Afatinib to shut down the escape routes (EGFR/HER2) the cancer uses to survive.
​Disable the Backup: Using SD36 to kill the emergency survival protein (STAT3).
​The Result?
Complete tumor disappearance. No relapse for over 200 days. Minimal side effects.
​We aren’t at human trials yet, but for the first time in decades, the conversation has shifted from "managing the disease" to "designing a cure."
​Science just proved that even the most adaptable cancer has its limits. 🏥✨
​
